|
Liver carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
The miR-885-5p/HK2 axis strongly links aerobic glycolysis to carcinogenesis and may become a promising therapeutic target and prognostic predictor for HCC patients.
|
31614321 |
2019 |
|
Neoplasm Metastasis
|
0.330 |
Biomarker
|
phenotype |
BEFREE |
Mechanistically, miRNA-885-3p (miR-885-3p) could inhibit the cell proliferation and metastasis in GC by negatively regulating the expression of cyclin-dependent kinase 4 (CDK4) at the post-transcriptional level.
|
29789536 |
2018 |
|
Neoplasm Metastasis
|
0.330 |
AlteredExpression
|
phenotype |
BEFREE |
Our findings demonstrated the overexpression of miR-885-5p in liver metastasis and its roles in inducing CRC metastasis, potentiating development of miR-885-5p inhibitor to treat advanced CRC in the future.
|
28460469 |
2017 |
|
Neoplasm Metastasis
|
0.330 |
Therapeutic
|
phenotype |
CTD_human |
The present study indicates that miR-885-5p suppresses the metastasis of HCC and inhibits Wnt/β-catenin signaling pathway by its CTNNB1 target, which suggests that miR-885-5p to be a promising negative regulator of HCC progression and as a novel therapeutic agent to treat HCC.
|
27738331 |
2016 |
|
Neoplasm Metastasis
|
0.330 |
Biomarker
|
phenotype |
BEFREE |
The present study indicates that miR-885-5p suppresses the metastasis of HCC and inhibits Wnt/β-catenin signaling pathway by its CTNNB1 target, which suggests that miR-885-5p to be a promising negative regulator of HCC progression and as a novel therapeutic agent to treat HCC.
|
27738331 |
2016 |
|
Liver carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Using miRNA panel of miR-122, miR-885-5p, and miR-29b with alpha fetoprotein (AFP) provided high diagnostic accuracy (AUC = 1) for early detection of HCC in normal population while using miRNA panel of miR-122, miR-885-5p, miR-221, and miR-22 with AFP provided high diagnostic accuracy (AUC = 0.982) for early detection of HCC in LC patients.
|
27271989 |
2016 |
|
Liver carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
The present study indicates that miR-885-5p suppresses the metastasis of HCC and inhibits Wnt/β-catenin signaling pathway by its CTNNB1 target, which suggests that miR-885-5p to be a promising negative regulator of HCC progression and as a novel therapeutic agent to treat HCC.
|
27738331 |
2016 |
|
Liver carcinoma
|
0.330 |
Therapeutic
|
disease |
CTD_human |
The present study indicates that miR-885-5p suppresses the metastasis of HCC and inhibits Wnt/β-catenin signaling pathway by its CTNNB1 target, which suggests that miR-885-5p to be a promising negative regulator of HCC progression and as a novel therapeutic agent to treat HCC.
|
27738331 |
2016 |
|
Liver Cirrhosis
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
These data suggested that miR-34a, miR-122, and miR-885-5p levels may be more related to the inflammatory process and ongoing hepatocyte damage in patients with cirrhosis.
|
29935272 |
2018 |
|
Liver Cirrhosis
|
0.310 |
Biomarker
|
disease |
CTD_human |
We previously reported that compared to health controls, patients with liver cirrhosis present the highest levels of circulating miR-885-5p, followed by those with chronic hepatitis B and those with HCC.
|
27738331 |
2016 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Hepatitis B
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Liver Cirrhosis, Alcoholic
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Chemical and Drug Induced Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Chemically-Induced Liver Toxicity
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Disease Exacerbation
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
miR-885-5p suppresses hepatocellular carcinoma metastasis and inhibits Wnt/β-catenin signaling pathway.
|
27738331 |
2016 |
|
Fibrosis, Liver
|
0.300 |
Biomarker
|
disease |
CTD_human |
miR-885-5p suppresses hepatocellular carcinoma metastasis and inhibits Wnt/β-catenin signaling pathway.
|
27738331 |
2016 |
|
Hepatitis B, Chronic
|
0.300 |
Biomarker
|
disease |
CTD_human |
We previously reported that compared to health controls, patients with liver cirrhosis present the highest levels of circulating miR-885-5p, followed by those with chronic hepatitis B and those with HCC.
|
27738331 |
2016 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
MiRNA functional analysis in combination with Kaplan-Meier survival analysis suggest that hsa-miR-885-5p could act as a tumor suppressor and should be validated as a potential prognostic biomarker in pancreatic cancer.
|
31311505 |
2019 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Furthermore, the target of miR-885-5p was predicted and confirmed using a luciferase reporter assay. miR-885-5p was demonstrated to be upregulated and SOCS was downregulated in colorectal cancer tissue, and cells. miR-885-5p suppression significantly inhibited tumor cell proliferation and migration, promoted E-cadherin expression, and inhibited the expression levels of N-cadherin, vimentin and Snail.
|
29928388 |
2018 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
While PIK3R1, HACE1, miR-139-3p, and miR-885-5p may act as tumor suppressor genes in the studied tumour type, miR-21-3p and miR-525-5p seem to have oncogenic properties.
|
27002759 |
2016 |